ClinicalTrials.gg
WithdrawnNCT02321306CASCADEUpdated Mar 19, 2019

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

A Phase 2 interventional study of LUM001 in Primary Biliary Cirrhosis, sponsored by Mirum Pharmaceuticals, Inc.. Withdrawn at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study stopped early, before enrolling its first participant.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
64th of 65
0 · median 46
Started
2015
with 4 others
Phase 2
34 of 83
2 open now
Registered
27th of 83
by date
Lead sponsor
3 of 83
Mirum Pharmaceuticals, Inc.

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 64th largest by enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2015, is one of 34 in phase 2, and was the 27th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

Open-label, multicenter study in adults with Primary Biliary Cirrhosis (PBC) designed to evaluate the long-term safety and tolerability of daily dosing with LUM001.

Read the detailed description

This is an open-label study in subjects with PBC who previously completed the LUM001 201 (CLARITY) study. The study is designed to investigate the long-term safety and tolerability of LUM001 treatment, with daily dosing for up to 2 years. Changes over time, compared to baseline, in liver enzymes, other biochemical markers associated with PBC, pruritus, and other quality of life measures will also be assessed.

03

Conditions studied

  • Primary Biliary Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed a core treatment protocol of LUM001 in the treatment of Primary Biliary Cirrhosis.
  2. Ability to understand and willingness to sign /assent prior to initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Presence of advanced liver disease.
  2. History of non-adherence during the subject's participation in the core LUM001 treatment protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LUM001

    LUM001 administered orally once each day.

    Drug: LUM001

Interventions

  • DrugLUM001

    LUM001 administered orally once each day.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety

    Adverse events, serious adverse events, changes in vital signs, laboratory and physical exam findings, and concommitant medication usage from baseline to Week 104

    Time frame: 2 years

Secondary outcomes

  1. Efficacy analysis as changes in liver enzymes and other biochemical markers from baseline to Week 104

    Alkaline phosphatase

    Time frame: 2 years

  2. Efficacy analysis as changes in liver enzymes and other biochemical markers from baseline to Week 104

    Liver enzymes (ALT, AST)

    Time frame: 2 years

  3. Efficacy analysis as changes in liver enzymes and other biochemical markers from baseline to Week 104

    Fasting serum bile acid

    Time frame: 2 years

  4. Efficacy analysis as changes in liver enzymes and other biochemical markers from baseline to Week 104

    C4

    Time frame: 2 years

  5. Efficacy analysis as changes in liver enzymes and other biochemical markers from baseline to Week 104

    Quality of life assessments (itch and sleep scores)

    Time frame: 2 years

07

Study locations

18 sites
  • Scripps Clinic
    La Jolla, California 92037, United States
  • University of California at Davis
    Sacramento, California 95817, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Minnesota Gastroenterology
    Saint Paul, Minnesota 55114, United States
  • St. Louis University
    Saint Louis, Missouri 63104, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Liver Institute of Virginia
    Newport News, Virginia 23602, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • University of Washington Harborview Medical Center
    Seattle, Washington 98104, United States
  • University of Birmingham
    Birmingham, England B15 2TT, United Kingdom
  • Royal Liverpool & Broadgreen University Hospital
    Liverpool, England L7 8XP, United Kingdom
  • Newcastle University
    Newcastle Upon Tyne, England NE1 4LP, United Kingdom
  • Oxford University Hospitals (John Radcliffe)
    Oxford, England OX3 9DU, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Dec 2017 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2014
First posted
Dec 22, 2014
Start
May 2015
Primary completionEst.
Dec 2017
CompletionEst.
Mar 2018
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02321306
Responsible party
Sponsor
First posted
Dec 22, 2014
Start date
May 2015
Primary completion
Dec 2017 (estimated)
Completion
Mar 2018 (estimated)
Last update
Mar 19, 2019

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion